Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Blopress

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Blopress was produced by Takeda.

Takeda CEO admits to Blopress mis-marketing

Takeda CEO admits to Blopress mis-marketing

Takeda CEO admits to Blopress mis-marketing. Campaign used graph indicating drug was superior to Pfizer’ s Norvasc. ... Blopress - also sold as Atacand - was a big seller for Takeda for many years, with sales approaching $2bn before it lost patent

Takeda rides out Actos decline as fiscal 2012 sales rise

Takeda rides out Actos decline as fiscal 2012 sales rise steep decline for antihypertensive Blopress (candesartan), also on generic competition, which ended the year down 22 per cent to 169bn yen. ... The drug's US launch is due in the summer. Azilva also contributed to Takeda's domestic sales growth on the

Acquisitions soften Actos blow in Takeda's first-half results

Acquisitions soften Actos blow in Takeda's first-half results As expected, Actos (pioglitazone) saw its sales slump 46 per cent to 92bn yen, while there were also significant declines for other drugs exposed to generic competition, notably antihypertensive Blopress (candesartan)

Takeda set for US sales slump as generic Actos arrives

Takeda set for US sales slump as generic Actos arrives Added to that, Takeda is also facing declining sales of another of its top products as a result of generic competition, such as antihypertensive Blopress (candesartan cilexetil) which had first-quarter

Result pages: 1 | 2 | 3 | 4 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics